Polydeoxyribonucleotide — PDRN — has become one of the most talked-about ingredients in Asian beauty over the past two years. Derived primarily from salmon sperm DNA and purified into short chain fragments of between 50 and 1,500 kDa, PDRN has a genuine medical pedigree stretching back decades. Its journey from clinical wound-care treatment to mainstream serums and ampoules, however, raises questions that every informed consumer should consider before reaching for a product bearing the ingredient's name.

What the research actually shows

The scientific case for PDRN rests on a well-characterised mechanism. It functions as an agonist of the adenosine A2A receptor, a signalling switch involved in tissue repair, inflammation modulation, and cell proliferation. Peer-reviewed research published in journals such as Frontiers in Pharmacology and PLOS One confirms that PDRN promotes fibroblast growth, stimulates collagen synthesis, enhances capillary formation via vascular endothelial growth factor (VEGF), and exhibits anti-inflammatory properties. A 2025 study in PLOS One demonstrated that PDRN inhibited UV-induced cellular ageing in keratinocytes by upregulating SIRT1 expression and reducing nuclear autophagy.

Clinical trials in wound healing are where PDRN's track record is most robust. A 2014 trial by Squadrito et al showed that PDRN significantly accelerated the healing of chronic diabetic foot ulcers when administered as an injectable. A 2004 pilot study by Valdatta et al found that PDRN-treated skin graft donor sites re-epithelialised almost twice as fast as untreated controls.

The strongest evidence for PDRN comes from injectable wound-healing studies — not from topical serums applied to intact skin.

The delivery problem

Almost all of the compelling clinical data involves PDRN administered via injection, delivering the ingredient directly into the dermis. The 500-Dalton rule — a widely accepted dermatological principle — holds that molecules larger than 500 Da struggle to penetrate the stratum corneum meaningfully. PDRN has a molecular weight of approximately 132,000 Da. That is more than 260 times larger than the penetration threshold.

This does not mean topical PDRN products are worthless. PDRN may offer surface-level hydration and soothing benefits, and some newer formulations employ nano-encapsulation or liposomal delivery systems that claim to improve bioavailability. However, the gap between injectable evidence and topical reality is one that many brands gloss over entirely.

Marketing versus mechanism

Several patterns have emerged that consumers should be wary of. Many brands cite injectable studies to promote their topical serums — a comparison that is scientifically misleading. The sensational framing of PDRN as "salmon DNA" functions more as a curiosity hook than a meaningful description. Concentration transparency remains poor across the market: some brands disclose PPM figures without addressing molecular stability, bioavailability, or delivery technology.

The emergence of plant-derived PDRN from sources like ginseng and Lactobacillus adds further complexity. Whilst ginseng-derived PDRN has shown some early promise in activating A2A receptor pathways in preclinical studies, evidence for plant-based PDRN in human skin remains in its earliest stages.

A balanced verdict

PDRN is not a scam — it is a biologically active material with a legitimate mechanism and a genuine medical heritage. But the leap from injectable tissue-repair therapy to over-the-counter anti-ageing serum involves more than simply changing the format. For consumers expecting the collagen-boosting, wrinkle-reducing results that injectable studies demonstrate, expectations should be tempered considerably. The smartest approach is to evaluate the formulation as a whole — delivery system, supporting ingredients, and brand transparency — rather than being seduced by a single headline ingredient.

References: Squadrito F et al. Curr Vasc Pharmacol. 2014. Valdatta L et al. J Int Med Res. 2004. Benlidayi IC. Rheumatol Int. 2019.